OKYO Pharma Limited (OKYO)Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
1.40 USD
-0.03
(-2.091%) ⇩
(Oct. 16, 2026, 11:26 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:32 a.m. EDT
The immediate outlook remains neutral despite a recent price bounce, as the stock trades below its 50-day moving average and the statistical forecast offers only a weak, low-confidence lean upward. While insiders have been aggressively buying shares, suggesting confidence in the company's pipeline, the underlying business fundamentals are severely impaired. The company is burning significant cash with negative operating and free cash flows, and both return on assets and equity are deeply negative, indicating a struggle to generate value from its operations. Furthermore, the forward P/E is negative due to expected losses, and the book value is negligible at $0.24 per share, meaning the current price of $1.42 represents a massive premium to the company's tangible assets. With no dividend to provide income and a history of significant annual declines prior to the latest recovery, the investment case relies entirely on speculative hopes regarding future clinical trial results rather than any current financial strength or sustainable profitability. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.060888 |
| AutoARIMA | 0.060941 |
| MSTL | 0.069926 |
| AutoTheta | 0.070118 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 4.99 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.503 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 73,476,584 |
| Forward P/E | -2.12 |
| Beta | -0.06 |
| Website | https://okyopharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.36160713 |
| Address1 | 35a Albemarle St |
| Address2 | Floor 2 |
| All Time High | 7.0 |
| All Time Low | 0.808 |
| Ask | 1.34 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 45,950 |
| Average Daily Volume3 Month | 81,360 |
| Average Volume | 81,360 |
| Average Volume10Days | 45,950 |
| Beta | -0.058 |
| Bid | 1.42 |
| Bid Size | 2 |
| Book Value | 0.235 |
| City | London |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.4001 |
| Current Ratio | 2.427 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.43 |
| Day Low | 1.4001 |
| Display Name | OKYO Pharma |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,723,561,200 |
| Earnings Timestamp Start | 1,723,561,200 |
| Ebitda | -8,497,733 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.408 |
| Enterprise Value | 54,451,456 |
| Eps Current Year | -0.12 |
| Eps Forward | -0.66 |
| Eps Trailing Twelve Months | -0.24 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.45746 |
| Fifty Day Average Change | -0.057360053 |
| Fifty Day Average Change Percent | -0.039356176 |
| Fifty Two Week Change Percent | -36.160713 |
| Fifty Two Week High | 3.2 |
| Fifty Two Week High Change | -1.7999 |
| Fifty Two Week High Change Percent | -0.56246877 |
| Fifty Two Week Low | 1.265 |
| Fifty Two Week Low Change | 0.1351 |
| Fifty Two Week Low Change Percent | 0.106798425 |
| Fifty Two Week Range | 1.265 - 3.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,652,794,200,000 |
| Float Shares | 27,935,377 |
| Forward Eps | -0.66 |
| Forward P E | -2.1213636 |
| Free Cashflow | -2,104,482 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | -0.029899955 |
| Fullday Change Percent | -2.090906 |
| Fullday Price | 1.4001 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -6,690,509 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31131 |
| Held Percent Institutions | 0.20099 |
| Implied Shares Outstanding | 52,479,527 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. |
| Long Name | OKYO Pharma Limited |
| Market | us_market |
| Market Cap | 73,476,584 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_45535051 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -8,949,657 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 68,223,385 |
| Number Of Analyst Opinions | 3 |
| Open | 1.43 |
| Operating Cashflow | -5,935,900 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 44 20 7495 2379 |
| Previous Close | 1.43 |
| Price Eps Current Year | -11.6675005 |
| Price Hint | 4 |
| Price To Book | 5.9578724 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.403 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.029899955 |
| Regular Market Change Percent | -2.090906 |
| Regular Market Day High | 1.43 |
| Regular Market Day Low | 1.4001 |
| Regular Market Day Range | 1.4001 - 1.43 |
| Regular Market Open | 1.43 |
| Regular Market Previous Close | 1.43 |
| Regular Market Price | 1.4001 |
| Regular Market Time | 1,792,164,403 |
| Regular Market Volume | 14,365 |
| Return On Assets | -0.43095002 |
| Return On Equity | -2.63784 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 52,479,527 |
| Shares Percent Shares Out | 0.0007 |
| Shares Short | 34,643 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 54,269 |
| Short Name | OKYO Pharma Limited |
| Short Percent Of Float | 0.0008 |
| Short Ratio | 0.42 |
| Source Interval | 15 |
| Symbol | OKYO |
| Target High Price | 13.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 8.33333 |
| Target Median Price | 7.0 |
| Total Cash | 20,594,268 |
| Total Cash Per Share | 0.392 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.66994 |
| Two Hundred Day Average Change | -0.26984 |
| Two Hundred Day Average Change Percent | -0.16158664 |
| Type Disp | Equity |
| Volume | 14,365 |
| Website | https://okyopharma.com |
| Zip | W1S 4JE |